These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31114700)

  • 1. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
    Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
    Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
    J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
    Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
    Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
    Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M
    Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
    Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
    Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.
    Hinton W; Feher M; Munro N; Joy M; de Lusignan S
    Diabet Med; 2020 Sep; 37(9):1499-1508. PubMed ID: 32128875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
    Scheen AJ
    Rev Med Suisse; 2020 Aug; 16(703):1483-1488. PubMed ID: 32852168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
    Wong ND; Fan W; Pak J
    Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.
    Antonazzo IC; Rozza D; Cortesi PA; Fornari C; Zanzottera Ferrari E; Paris C; Eteve-Pitsaer C; Gnesi M; Mele S; D'Amelio M; Maurizi AR; Palladino P; Mantovani LG; Mazzaglia G
    Acta Diabetol; 2024 Aug; ():. PubMed ID: 39207490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.